AR022589A1 - UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER - Google Patents

UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER

Info

Publication number
AR022589A1
AR022589A1 ARP000100627A ARP000100627A AR022589A1 AR 022589 A1 AR022589 A1 AR 022589A1 AR P000100627 A ARP000100627 A AR P000100627A AR P000100627 A ARP000100627 A AR P000100627A AR 022589 A1 AR022589 A1 AR 022589A1
Authority
AR
Argentina
Prior art keywords
oral administration
spontanely
dispersable
pharmaceutical composition
preparation
Prior art date
Application number
ARP000100627A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR022589(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR022589A1 publication Critical patent/AR022589A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP000100627A 1999-02-16 2000-02-14 UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER AR022589A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9903547.9A GB9903547D0 (en) 1999-02-16 1999-02-16 Organic compounds

Publications (1)

Publication Number Publication Date
AR022589A1 true AR022589A1 (es) 2002-09-04

Family

ID=10847896

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP000100627A AR022589A1 (es) 1999-02-16 2000-02-14 UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER
ARP110102851A AR082579A2 (es) 1999-02-16 2011-08-05 Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110102851A AR082579A2 (es) 1999-02-16 2011-08-05 Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad

Country Status (34)

Country Link
US (3) US20020061873A1 (cg-RX-API-DMAC10.html)
EP (1) EP1152750B1 (cg-RX-API-DMAC10.html)
JP (2) JP5057610B2 (cg-RX-API-DMAC10.html)
KR (2) KR100880859B1 (cg-RX-API-DMAC10.html)
CN (1) CN100367930C (cg-RX-API-DMAC10.html)
AR (2) AR022589A1 (cg-RX-API-DMAC10.html)
AT (1) ATE430554T1 (cg-RX-API-DMAC10.html)
AU (1) AU765776B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0008228B8 (cg-RX-API-DMAC10.html)
CA (1) CA2362277C (cg-RX-API-DMAC10.html)
CL (1) CL2009001682A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ303979B6 (cg-RX-API-DMAC10.html)
DE (1) DE60042151D1 (cg-RX-API-DMAC10.html)
DK (1) DK1152750T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP083351A (cg-RX-API-DMAC10.html)
ES (1) ES2326783T3 (cg-RX-API-DMAC10.html)
GB (1) GB9903547D0 (cg-RX-API-DMAC10.html)
HK (1) HK1045807B (cg-RX-API-DMAC10.html)
HU (1) HUP0105364A3 (cg-RX-API-DMAC10.html)
ID (1) ID30504A (cg-RX-API-DMAC10.html)
IL (3) IL144512A0 (cg-RX-API-DMAC10.html)
MY (1) MY128362A (cg-RX-API-DMAC10.html)
NO (1) NO331232B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ513529A (cg-RX-API-DMAC10.html)
PE (1) PE20001499A1 (cg-RX-API-DMAC10.html)
PL (1) PL198330B1 (cg-RX-API-DMAC10.html)
PT (1) PT1152750E (cg-RX-API-DMAC10.html)
RU (1) RU2266121C2 (cg-RX-API-DMAC10.html)
SI (1) SI1152750T1 (cg-RX-API-DMAC10.html)
SK (1) SK286967B6 (cg-RX-API-DMAC10.html)
TR (1) TR200102385T2 (cg-RX-API-DMAC10.html)
TW (1) TWI240636B (cg-RX-API-DMAC10.html)
WO (1) WO2000048571A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200106677B (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
WO2002076432A2 (en) * 2001-03-26 2002-10-03 Novartis Ag Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
AU2002342335B2 (en) 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
PT1441737E (pt) * 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
CN101897662B (zh) * 2002-07-23 2013-05-22 诺瓦提斯公司 包含药物、软膏基质和增溶剂/分散剂的眼用软膏剂组合物
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
WO2008021347A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
RU2560677C2 (ru) * 2009-12-22 2015-08-20 Лео Фарма А/С Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
WO2013042069A1 (en) 2011-09-22 2013-03-28 Ariel-University Research And Development Company, Ltd. Emulsions and methods of making emulsions
RU2742650C2 (ru) * 2015-12-09 2021-02-09 Фосфейдженикс Лимитед Фармацевтический состав
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE3824034C1 (cg-RX-API-DMAC10.html) * 1988-07-15 1989-09-14 Gustav 7290 Freudenstadt De Memminger
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
DE69229779T2 (de) 1991-04-19 1999-12-23 Lds Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DK0589843T3 (da) * 1992-09-25 2002-04-02 Novartis Ag Cyclosporinholdige farmaceutiske præparater
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
JPH09510182A (ja) 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
WO1995022331A1 (en) 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
MY129435A (en) * 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
GB2308545B (en) 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
EP0711556A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Intravenöse Lösungen für ein Staurosporinderivat
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
WO1998013032A1 (en) 1996-09-27 1998-04-02 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
PT988046E (pt) * 1997-01-30 2004-12-31 Novartis Ag Composicoes farmaceuticas sem oleo contendo ciclosporina a
SI0999826T1 (en) 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
DK0999838T3 (da) 1997-07-29 2002-07-08 Upjohn Co Selv-emulgerende formulering for lipofile forbindelser
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AR013276A1 (es) 1998-07-31 2000-12-13 Panacea Biotec Ltd Composicion de ciclosporina transparente
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
PL198330B1 (pl) 2008-06-30
WO2000048571A1 (en) 2000-08-24
HUP0105364A2 (hu) 2002-05-29
JP2002537242A (ja) 2002-11-05
NZ513529A (en) 2003-10-31
GB9903547D0 (en) 1999-04-07
CN100367930C (zh) 2008-02-13
US20140056974A1 (en) 2014-02-27
ATE430554T1 (de) 2009-05-15
US8722664B2 (en) 2014-05-13
IL144512A0 (en) 2002-05-23
US8575147B2 (en) 2013-11-05
SI1152750T1 (sl) 2009-10-31
DK1152750T3 (da) 2009-08-24
NO20013964D0 (no) 2001-08-15
JP5057610B2 (ja) 2012-10-24
CZ303979B6 (cs) 2013-07-31
BRPI0008228B8 (pt) 2021-05-25
NO20013964L (no) 2001-10-15
BR0008228A (pt) 2001-10-30
AR082579A2 (es) 2012-12-19
KR100880859B1 (ko) 2009-01-30
HK1045807B (zh) 2008-12-05
CA2362277A1 (en) 2000-08-24
HK1045807A1 (zh) 2002-12-13
KR20080064914A (ko) 2008-07-09
CA2362277C (en) 2010-03-30
KR20010093281A (ko) 2001-10-27
RU2266121C2 (ru) 2005-12-20
ECSP083351A (es) 2008-08-29
PT1152750E (pt) 2009-08-07
BRPI0008228B1 (pt) 2016-08-23
EP1152750A1 (en) 2001-11-14
AU3154200A (en) 2000-09-04
DE60042151D1 (de) 2009-06-18
PL350556A1 (en) 2002-12-16
US20020061873A1 (en) 2002-05-23
IL192666A0 (en) 2009-02-11
MY128362A (en) 2007-01-31
JP2012111763A (ja) 2012-06-14
SK286967B6 (sk) 2009-08-06
HUP0105364A3 (en) 2003-02-28
CN1339963A (zh) 2002-03-13
PE20001499A1 (es) 2001-01-12
IL144512A (en) 2011-03-31
CZ20012931A3 (cs) 2001-11-14
EP1152750B1 (en) 2009-05-06
SK11722001A3 (sk) 2001-12-03
US20080070897A1 (en) 2008-03-20
ES2326783T3 (es) 2009-10-20
AU765776B2 (en) 2003-10-02
CL2009001682A1 (es) 2010-07-23
TWI240636B (en) 2005-10-01
ZA200106677B (en) 2003-01-14
ID30504A (id) 2001-12-13
TR200102385T2 (tr) 2002-09-23
NO331232B1 (no) 2011-11-07

Similar Documents

Publication Publication Date Title
ECSP083351A (es) Composiciones farmacéuticas
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
UY27908A1 (es) Formulaciones y formas de dosificación para la administración controlada de topiramato
DK1318788T3 (da) Nanopartikulær fastdosissammensætninger
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
DK1256343T3 (da) Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
EP1061915A4 (en) PHARMACEUTICAL FORMULATIONS OF TAXANES
CR6326A (es) Formulaciones farmaceuticas de liberacion controlada
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
AR025938A1 (es) Nuevas composiciones farmaceuticas.
DE60313359D1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
CY1118057T1 (el) Φαρμακευτικη συνθεση για στοματικη χορηγηση
JOP20220335A1 (ar) تركيبات صيدلانية تحتوي على مواد تطلق إنتيروكين في صورة جرعات متعددة في توليف مع عوامل تهلم
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
AR025060A1 (es) Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa
ES2194618T1 (es) Composicion oralmente desintegrable que comprende mirtazapina.
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
HN2001000038A (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
ES2325291A1 (es) "uso de un extracto de silybum marianum"
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
ATE462419T1 (de) Orale pharmazeutische zusammensetzung für weichkapseln mit vinorelbin und behandlungsverfahren
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica
ECSP003351A (es) Composiciones farmaceuticas

Legal Events

Date Code Title Description
FC Refusal